These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34921666)

  • 1. Measuring Burden of Illness in Phenylketonuria (PKU): Development of the PKU Symptom Severity and Impacts Scale as a Robust Patient-Reported Outcome.
    Quinn J; Georgiadis A; Lewis HB; Jurecki E
    Adv Ther; 2022 Feb; 39(2):971-991. PubMed ID: 34921666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-interventional observational study to identify and validate clinical outcome assessments for adults with phenylketonuria for use in clinical trials.
    Burton BK; Skalicky A; Baerwald C; Bilder DA; Harding CO; Ilan AB; Jurecki E; Longo N; Madden DT; Sivri HS; Wilcox G; Thomas J; Delaney K
    Mol Genet Metab Rep; 2021 Dec; 29():100810. PubMed ID: 34815941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.
    Jahja R; Huijbregts SC; de Sonneville LM; van der Meere JJ; Bosch AM; Hollak CE; Rubio-Gozalbo ME; Brouwers MC; Hofstede FC; de Vries MC; Janssen MC; van der Ploeg AT; Langendonk JG; van Spronsen FJ
    Mol Genet Metab; 2013; 110 Suppl():S57-61. PubMed ID: 24183792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients' and parents' quality of life: the phenylketonuria - quality of life (PKU-QOL) questionnaires.
    Regnault A; Burlina A; Cunningham A; Bettiol E; Moreau-Stucker F; Benmedjahed K; Bosch AM
    Orphanet J Rare Dis; 2015 May; 10():59. PubMed ID: 25958326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emotional health in early-treated adults with phenylketonuria (PKU): Relationship with cognitive abilities and blood phenylalanine.
    Palermo L; MacDonald A; Limback E; Robertson L; Howe S; Geberhiwot T; Romani C
    J Clin Exp Neuropsychol; 2020 Mar; 42(2):142-159. PubMed ID: 31790339
    [No Abstract]   [Full Text] [Related]  

  • 6. Psychosocial functioning in children with phenylketonuria: Relationships between quality of life and parenting indicators.
    Morawska A; Mitchell AE; Etel E; Kirby G; McGill J; Coman D; Inwood A
    Child Care Health Dev; 2020 Jan; 46(1):56-65. PubMed ID: 31782540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries.
    Bosch AM; Burlina A; Cunningham A; Bettiol E; Moreau-Stucker F; Koledova E; Benmedjahed K; Regnault A
    Orphanet J Rare Dis; 2015 Jun; 10():80. PubMed ID: 26084935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The course of life and quality of life of early and continuously treated Dutch patients with phenylketonuria.
    Bosch AM; Tybout W; van Spronsen FJ; de Valk HW; Wijburg FA; Grootenhuis MA
    J Inherit Metab Dis; 2007 Feb; 30(1):29-34. PubMed ID: 17160615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of phenylketonuria on PKU patients' quality of life: Using of the phenylketonuria-quality of life (PKU-QOL) questionnaires.
    Alptekin IM; Koc N; Gunduz M; Cakiroglu FP
    Clin Nutr ESPEN; 2018 Oct; 27():79-85. PubMed ID: 30144897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome (PRO) Instrument.
    Johnson CD; Arbuckle R; Bonner N; Connett G; Dominguez-Munoz E; Levy P; Staab D; Williamson N; Lerch MM
    Patient; 2017 Oct; 10(5):615-628. PubMed ID: 28332032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cognitive and psychosocial outcomes in adults with phenylketonuria.
    Aitkenhead L; Krishna G; Ellerton C; Moinuddin M; Matcham J; Shiel L; Hossain S; Kiffin M; Foley J; Skeath R; Cleary M; Lachmann R; Murphy E
    J Inherit Metab Dis; 2021 Nov; 44(6):1353-1368. PubMed ID: 34145605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatric symptoms and disorders in phenylketonuria.
    Brumm VL; Bilder D; Waisbren SE
    Mol Genet Metab; 2010; 99 Suppl 1():S59-63. PubMed ID: 20123472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the US English version of the phenylketonuria - quality of life (PKU-QOL) questionnaire.
    Jurecki E; Cunningham A; Birardi V; Gagol G; Acquadro C
    Health Qual Life Outcomes; 2017 Mar; 15(1):46. PubMed ID: 28274259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.
    Mathias SD; Vallow S; Gipson DS; Thorneloe KS; Sprecher D
    Am J Kidney Dis; 2017 Oct; 70(4):532-540. PubMed ID: 28663063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH.
    McCollister D; Shaffer S; Badesch DB; Filusch A; Hunsche E; Schüler R; Wiklund I; Peacock A;
    Respir Res; 2016 Jun; 17(1):72. PubMed ID: 27301413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria.
    Boot E; Hollak CEM; Huijbregts SCJ; Jahja R; van Vliet D; Nederveen AJ; Nieman DH; Bosch AM; Bour LJ; Bakermans AJ; Abeling NGGM; Bassett AS; van Amelsvoort TAMJ; van Spronsen FJ; Booij J
    Psychol Med; 2017 Dec; 47(16):2854-2865. PubMed ID: 28552082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for cognitive and social-emotional problems in individuals with PKU: tools for use in the metabolic clinic.
    Waisbren S; White DA
    Mol Genet Metab; 2010; 99 Suppl 1():S96-9. PubMed ID: 20123479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of the life quality in children with phenylketonuria].
    Bushueva TV; Vinyarskaya IV; Chernikov VV; Borovik TE; Kuzenkova LM
    Vestn Ross Akad Med Nauk; 2014; (11-12):39-45. PubMed ID: 25971125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study.
    Jahja R; van Spronsen FJ; de Sonneville LMJ; van der Meere JJ; Bosch AM; Hollak CEM; Rubio-Gozalbo ME; Brouwers MCGJ; Hofstede FC; de Vries MC; Janssen MCH; van der Ploeg AT; Langendonk JG; Huijbregts SCJ
    J Inherit Metab Dis; 2016 May; 39(3):355-362. PubMed ID: 26914933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of metabolic control and tetrahydrobiopterin treatment on health related quality of life of patients with early-treated phenylketonuria: A PKU-COBESO study.
    Huijbregts SCJ; Bosch AM; Simons QA; Jahja R; Brouwers MCGJ; De Sonneville LMJ; De Vries MC; Hofstede FC; Hollak CEM; Janssen MCH; Langendonk JG; Rubio-Gozalbo ME; Van der Meere JJ; Van der Ploeg AT; Van Spronsen FJ
    Mol Genet Metab; 2018 Sep; 125(1-2):96-103. PubMed ID: 30007854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.